Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is seeking a Director of Global Regulatory Affairs – CMC to lead their global chemical, manufacturing, and controls (CMC) regulatory strategy for their biopharmaceutical products. The role involves ensuring compliance with global regulations, managing interactions with health authorities, and leading regulatory submissions to facilitate clinical development and commercialization.
Headquarters
Boston, Massachusetts, United States
Company Size
201-500 employees
Founded
1998
Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. The company commercializes LINZESS® (linaclotide), an approved treatment for conditions including irritable bowel syndrome with constipation and functional constipation, and maintains an active pipeline targeting additional GI indications such as Short Bowel Syndrome. With a singular focus on GI and patient-focused research, Ironwood combines scientific innovation with commercial expertise to improve outcomes for the millions of Americans affected by digestive diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals confirms liquidity conditions for credit facility maturity
5 days ago
Senior Director, Regulatory Affairs CMC
Mirum Pharmaceuticals
Associate Director, Global Regulatory Affairs CMC
Takeda Pharmaceutical Company Limited
Global Regulatory Affairs CMC Lead
City of Pierre, South Dakota
Director, CMC Regulatory Affairs
Regeneron Pharmaceuticals
Senior Director, Regulatory Affairs CMC
Alcon
Senior Director, Regulatory Affairs, CMC
Summit Therapeutics,